From:
`To:
`Subject:
`Date:
`
`ded_nefreply@ded.uscourts.gov
`ded_ecf@ded.uscourts.gov
`[EXT] Activity in Case . In Re: Ozempic (Semaglutide) Patent Litigation Stipulation
`Monday, February 26, 2024 3:41:44 PM
`
`This is an automatic e-mail message generated by the CM/ECF system. Please DO NOT
`RESPOND to this e-mail because the mail box is unattended.
`***NOTE TO PUBLIC ACCESS USERS*** Judicial Conference of the United States
`policy permits attorneys of record and parties in a case (including pro se litigants) to
`receive one free electronic copy of all documents filed electronically, if receipt is required
`by law or directed by the filer. PACER access fees apply to all other users. To avoid later
`charges, download a copy of each document during this first viewing. However, if the
`referenced document is a transcript, the free copy and 30 page limit do not apply.
`
`U.S. District Court
`
`District of Delaware
`
`Notice of Electronic Filing
`
`The following transaction was entered by Metzler, Sara on 2/26/2024 at 3:40 PM EST and
`filed on 2/26/2024
`Case Name:
`Case Number:
`Filer:
`
`Novo Nordisk Inc. et al v. Rio Biopharmaceuticals, Inc. et al
`1:22-cv-00294-CFC
`Sun Pharmaceutical Industries Ltd.
`Sun Pharmaceutical Industries Inc.
`Document Number: 275
`
`Docket Text:
`STIPULATION of Invalidity Contentions by Sun Pharmaceutical Industries Ltd.,
`Sun Pharmaceuticals Industries Inc., Sun Pharmaceutical Industries Inc..
`(Metzler, Sara)
`
`Case Name:
`Case Number:
`Filer:
`
`In Re: Ozempic (Semaglutide) Patent Litigation
`1:22-md-03038-CFC
`Sun Pharmaceutical Industries Ltd.
`Sun Pharmaceuticals Industries Inc.
`Document Number: 314
`
`Docket Text:
`STIPULATION of Invalidity Contentions by Sun Pharmaceutical Industries Ltd.,
`Sun Pharmaceuticals Industries Inc., Sun Pharmaceutical Industries Inc..
`(Metzler, Sara)
`
`1:22-cv-00294-CFC Notice has been electronically mailed to:
`
`Alexis Stombaugh astombaugh@ycst.com, corpcal@ycst.com, corporate@ycst.com
`
`Novo Nordisk Exhibit 2547
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`
`To:
`Subject:
`Date:
`
`ded_nefreply@ded.uscourts.gov
`ded_ecf@ded.uscourts.gov
`[EXT] Activity in Case . In Re: Ozempic (Semaglutide) Patent Litigation Stipulation
`Monday, February 26, 2024 3:41:44 PM
`
`This is an automatic e-mail message generated by the CM/ECF system. Please DO NOT
`RESPOND to this e-mail because the mail box is unattended.
`***NOTE TO PUBLIC ACCESS USERS*** Judicial Conference of the United States
`policy permits attorneys of record and parties in a case (including pro se litigants) to
`receive one free electronic copy of all documents filed electronically, if receipt is required
`by law or directed by the filer. PACER access fees apply to all other users. To avoid later
`charges, download a copy of each document during this first viewing. However, if the
`referenced document is a transcript, the free copy and 30 page limit do not apply.
`
`U.S. District Court
`
`District of Delaware
`
`Notice of Electronic Filing
`
`The following transaction was entered by Metzler, Sara on 2/26/2024 at 3:40 PM EST and
`filed on 2/26/2024
`Case Name:
`Case Number:
`Filer:
`
`Novo Nordisk Inc. et al v. Rio Biopharmaceuticals, Inc. et al
`1:22-cv-00294-CFC
`Sun Pharmaceutical Industries Ltd.
`Sun Pharmaceutical Industries Inc.
`Document Number: 275
`
`Docket Text:
`STIPULATION of Invalidity Contentions by Sun Pharmaceutical Industries Ltd.,
`Sun Pharmaceuticals Industries Inc., Sun Pharmaceutical Industries Inc..
`(Metzler, Sara)
`
`Case Name:
`Case Number:
`Filer:
`
`In Re: Ozempic (Semaglutide) Patent Litigation
`1:22-md-03038-CFC
`Sun Pharmaceutical Industries Ltd.
`Sun Pharmaceuticals Industries Inc.
`Document Number: 314
`
`Docket Text:
`STIPULATION of Invalidity Contentions by Sun Pharmaceutical Industries Ltd.,
`Sun Pharmaceuticals Industries Inc., Sun Pharmaceutical Industries Inc..
`(Metzler, Sara)
`
`1:22-cv-00294-CFC Notice has been electronically mailed to:
`
`Alexis Stombaugh astombaugh@ycst.com, corpcal@ycst.com, corporate@ycst.com
`
`Novo Nordisk Exhibit 2547
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`
`
`Alison M. King AMKing@winston.com
`
`Ashley Graham agraham@winston.com
`
`Brian P. Egan began@mnat.com, bpeefiling@mnat.com,
`mnat_IP_eFiling@morrisnichols.com
`
`Carolyn A. Blessing cblessing@lockelord.com, ewilson@lockelord.com
`
`Christopher B. Ferenc christopher.ferenc@katten.com, dawn.el-khoury@katten.com
`
`Christopher W. West christopher.west@katten.com
`
`David B. Abramowitz dabramowitz@lockelord.com, kim.ingle@lockelord.com
`
`Dominick T. Gattuso dgattuso@hegh.law, RMarshall@hegh.law
`
`Hannah M. Shankman hshankman@winston.com
`
`Jack B. Blumenfeld Jbbefiling@mnat.com, jblumenfeld@mnat.com,
`mnat_IP_eFiling@morrisnichols.com
`
`Jacob C. Britz jacob.britz@lockelord.com, AutoDocket@lockelord.com
`
`Jaimin H. Shah jshah@taftlaw.com, pskinner@taftlaw.com
`
`Jovial Wong jwong@winston.com
`
`Kelly E. Farnan farnan@rlf.com, linda-loveless-5548@ecf.pacerpro.com, loveless@rlf.com
`
`Kenneth Laurence Dorsney kdorsney@morrisjames.com, CHitch@morrisjames.com,
`ippara@morrisjames.com
`
`Michael J. Gaertner mgaertner@lockelord.com, mklimasara@lockelord.com
`
`Philip Y. Kouyoumdjian pkouyoumdjian@taftlaw.com, schang@taftlaw.com
`
`Pilar Gabrielle Kraman pkraman@ycst.com, corpcal@ycst.com, corporate@ycst.com
`
`Sharon Lin slin@winston.com
`
`Stephen R. Auten sauten@taftlaw.com, bkann@taftlaw.com
`
`Travis J Murray tmurray@morrisnichols.com
`
`1:22-cv-00294-CFC Filer will deliver document by other means to:
`
`1:22-md-03038-CFC Notice has been electronically mailed to:
`
`Alexis Stombaugh astombaugh@ycst.com, corpcal@ycst.com, corporate@ycst.com
`
`Novo Nordisk Exhibit 2547
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00002
`
`
`
`Alison M. King AMKing@winston.com
`
`Brandon M. White BMWhite@perkinscoie.com, docketwdc@perkinscoie.com
`
`Brian P. Egan began@mnat.com, bpeefiling@mnat.com,
`mnat_IP_eFiling@morrisnichols.com
`
`Bryan D. Beel bbeel@perkinscoie.com, khuang@perkinscoie.com
`
`Carolyn A. Blessing cblessing@lockelord.com, ewilson@lockelord.com
`
`Christopher B. Ferenc christopher.ferenc@katten.com, dawn.el-khoury@katten.com
`
`Christopher W. West christopher.west@katten.com
`
`David B. Abramowitz dabramowitz@lockelord.com, kim.ingle@lockelord.com
`
`Dominick T. Gattuso dgattuso@hegh.law, RMarshall@hegh.law
`
`Emily J. Greb egreb@perkinscoie.com, docketmadison@perkinscoie.com
`
`Gordon H. Copland Gordon.Copland@steptoe-johnson.com
`
`Hannah M. Shankman hshankman@winston.com
`
`Jack B. Blumenfeld Jbbefiling@mnat.com, jblumenfeld@mnat.com,
`mnat_IP_eFiling@morrisnichols.com
`
`Jacob C. Britz jacob.britz@lockelord.com, AutoDocket@lockelord.com
`
`Jovial Wong jwong@winston.com
`
`Kelly E. Farnan farnan@rlf.com, linda-loveless-5548@ecf.pacerpro.com, loveless@rlf.com
`
`Kenneth Laurence Dorsney kdorsney@morrisjames.com, CHitch@morrisjames.com,
`ippara@morrisjames.com
`
`Maria A. Stubbings MStubbings@perkinscoie.com
`
`Michael J. Gaertner mgaertner@lockelord.com, mklimasara@lockelord.com
`
`Pilar Gabrielle Kraman pkraman@ycst.com, corpcal@ycst.com, corporate@ycst.com
`
`Richard Charles Weinblatt weinblatt@swdelaw.com, filings@swdelaw.com
`
`Shannon M. Bloodworth SBloodworth@perkinscoie.com, DocketWDC@perkinscoie.com
`
`Sharon Lin slin@winston.com
`
`Stamatios Stamoulis stamoulis@swdelaw.com, bill.rodgers@viatris.com,
`
`Novo Nordisk Exhibit 2547
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00003
`
`
`
`filings@swdelaw.com, jill.ondos@viatris.com, matthew.greinert@viatris.com,
`preston.imperatore@viatris.com, Tom.Jenkins@viatris.com
`
`Travis J Murray tmurray@morrisnichols.com
`
`William J O'Brien William.Obrien@Steptoe-Johnson.com
`
`1:22-md-03038-CFC Filer will deliver document by other means to:
`
`The following document(s) are associated with this transaction:
`
`Document description:Main Document
`Original filename:n/a
`Electronic document Stamp:
`[STAMP dcecfStamp_ID=1079733196 [Date=2/26/2024] [FileNumber=5475773-0
`] [b414005bd342ee39699965a7989e1f22b5d3d00f2c795e0c9d6d89d2f0f28da6ebb
`6fd12c60af2b4609772e9348c08f6cbb5b8f322d833101bb62ebea34743bf]]
`
`Novo Nordisk Exhibit 2547
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00004
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
